Severity of BA.2 variant and vaccine effectiveness against symptomatic disease in Scotland

Steven Kerr; Chris Robertson; Sam Hillman; Zoe Grange; Christopher Sullivan; Aziz Sheikh

doi:10.1016/j.lanepe.2022.100533

Severity of BA.2 variant and vaccine effectiveness against symptomatic disease in Scotland

Steven Kerr, Chris Robertson, Sam Hillman, Zoe Grange, Christopher Sullivan, Aziz Sheikh

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Article number	100533
Pages (from-to)	100533
Journal	The Lancet Regional Health Europe
Volume	23
Early online date	4 Nov 2022
DOIs	https://doi.org/10.1016/j.lanepe.2022.100533
Publication status	Published - 1 Dec 2022

Access to Document

10.1016/j.lanepe.2022.100533

Severity of BA.2 variant and vaccine effectiveness against symptomatic disease in ScotlandFinal published version, 913 KBLicence: Creative Commons: Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND)

Cite this

@article{01ed17d2b1704e178789865d3a93d3f3,

title = "Severity of BA.2 variant and vaccine effectiveness against symptomatic disease in Scotland",

author = "Steven Kerr and Chris Robertson and Sam Hillman and Zoe Grange and Christopher Sullivan and Aziz Sheikh",

note = "Funding Information: This study is part of the EAVE II project. EAVE II is funded by the MRC (MC_PC_19075) with the support of BREATHE—The Health Data Research Hub for Respiratory Health (MC_PC_19004), which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (MC_PC_20058). Additional support has been provided through Public Health Scotland, the Scottish Government Director General Health and Social Care, and the University of Edinburgh. The original EAVE project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme (11/46/23). The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care, or the UK Government. We thank Dave Kelly from Albasoft (Inverness, UK) for his support with making primary care data available, and Wendy Inglis-Humphrey, Vicky Hammersley, and Laura Brook (University of Edinburgh, Edinburgh, UK) for their support with project management and administration. Funding Information: This study is part of the EAVE II project. EAVE II is funded by the MRC ( MC_PC_19075 ) with the support of BREATHE—The Health Data Research Hub for Respiratory Health (MC_PC_19004), which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation ( MC_PC_20058 ). Additional support has been provided through Public Health Scotland , the Scottish Government Director General Health and Social Care, and the University of Edinburgh . The original EAVE project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme (11/46/23). The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care, or the UK Government. We thank Dave Kelly from Albasoft (Inverness, UK) for his support with making primary care data available, and Wendy Inglis-Humphrey, Vicky Hammersley, and Laura Brook (University of Edinburgh, Edinburgh, UK) for their support with project management and administration. ",

year = "2022",

month = dec,

day = "1",

doi = "10.1016/j.lanepe.2022.100533",

language = "English",

volume = "23",

pages = "100533",

journal = "The Lancet Regional Health Europe",

issn = "2666-7762",

publisher = "Elsevier",

}

TY - JOUR

T1 - Severity of BA.2 variant and vaccine effectiveness against symptomatic disease in Scotland

AU - Kerr, Steven

AU - Robertson, Chris

AU - Hillman, Sam

AU - Grange, Zoe

AU - Sullivan, Christopher

AU - Sheikh, Aziz

N1 - Funding Information: This study is part of the EAVE II project. EAVE II is funded by the MRC (MC_PC_19075) with the support of BREATHE—The Health Data Research Hub for Respiratory Health (MC_PC_19004), which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (MC_PC_20058). Additional support has been provided through Public Health Scotland, the Scottish Government Director General Health and Social Care, and the University of Edinburgh. The original EAVE project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme (11/46/23). The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care, or the UK Government. We thank Dave Kelly from Albasoft (Inverness, UK) for his support with making primary care data available, and Wendy Inglis-Humphrey, Vicky Hammersley, and Laura Brook (University of Edinburgh, Edinburgh, UK) for their support with project management and administration. Funding Information: This study is part of the EAVE II project. EAVE II is funded by the MRC ( MC_PC_19075 ) with the support of BREATHE—The Health Data Research Hub for Respiratory Health (MC_PC_19004), which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation ( MC_PC_20058 ). Additional support has been provided through Public Health Scotland , the Scottish Government Director General Health and Social Care, and the University of Edinburgh . The original EAVE project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme (11/46/23). The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care, or the UK Government. We thank Dave Kelly from Albasoft (Inverness, UK) for his support with making primary care data available, and Wendy Inglis-Humphrey, Vicky Hammersley, and Laura Brook (University of Edinburgh, Edinburgh, UK) for their support with project management and administration.

PY - 2022/12/1

Y1 - 2022/12/1

U2 - 10.1016/j.lanepe.2022.100533

DO - 10.1016/j.lanepe.2022.100533

M3 - Comment/debate

C2 - 36373099

SN - 2666-7762

VL - 23

SP - 100533

JO - The Lancet Regional Health Europe

JF - The Lancet Regional Health Europe

M1 - 100533

ER -